Small Molecules in Development for the Treatment of Spinal Muscular Atrophy

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by low survival motor neuron (SMN) protein levels.
• SMN protein deficiency results from alternative splicing of the SMN2 gene, excluding critical codons.
• Currently, no FDA-approved treatments exist for SMA.

Purpose of the Study:

• To review repurposed drugs and novel small-molecule compounds for potential spinal muscular atrophy (SMA) treatment.
• To summarize therapeutic efforts in SMA, including early trials and recent drug discovery.

Main Methods:

• Literature review of clinical trials and studies on SMA therapeutics.
• Analysis of repurposed drugs (e.g., phenylbutyrate, valproic acid) and novel small molecules (e.g., olesoxime, RG3039).

Main Results:

• Early therapeutic efforts using repurposed drugs have not demonstrated clinical effectiveness in SMA patients.
• Recent clinical trials focus on novel small-molecule compounds developed through high-throughput screening and medicinal chemistry.

Conclusions:

• The review highlights the ongoing search for effective SMA treatments.
• Both repurposed drugs and newly discovered small molecules are under investigation for SMA therapy.